...
首页> 外文期刊>Nature reviews neuroscience >AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK
【24h】

AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK

机译:AZD1208,泛PIM激酶抑制剂,通过控制PIM-3,MTOR,4EBP-1,S6,STAT-3和AMPK的表达和磷酸化对93T449人脂质糖瘤细胞具有抗生长效应

获取原文
获取原文并翻译 | 示例

摘要

Overexpression of Pim kinases has an oncogenic/pro-survival role in many hematological and solid cancers. AZD1208 is a pan-Pim kinase inhibitor that has anti-cancer and anti-adipogenic actions. Here, we investigated the effects of AZD1208 on the growth of 93T449 cells, a differentiated human liposarcoma cell line. At 20 mu M, AZD1208 was cytotoxic (cytostatic) but not apoptotic, reducing cell survival without DNA fragmentation, caspase activation or increasing cells in the sub G1 phase; known apoptotic parameters. Notably, AZD1208 reduced phosphorylation of signal transducer and activator of transcription-3 (STAT-3) in 93T449 cells. STAT-3 inhibition by AG490, a JAK2/STAT-3 inhibitor similarly reduced cell survival. AZD1208 down-regulated phosphorylation of mammalian target of rapamycin (mTOR) and ribosomal S6 while up-regulated eukaryotic initiation factor-2 (eIF-2). In addition, AZD1208 induced a LKB-1-independent AMPK activation, which was crucial for its cytostatic effect, as knock-down of AMPK greatly blocked AZD1208s ability to reduce cell survival. AZD1208 had no effect on expression of two members of Pim kinase family (Pim-1 and Pim-3) but inhibited phosphorylation of 4EBP-1, a downstream effector of Pim kinases. Importantly, a central role for Pim-3 in the actions of AZD1208 was confirmed by knock-down, which not only reduced 93T449 cell survival but also led to the inhibition of 4EBP-1, mTOR, eIF-2 and STAT-3, along with the activation of AMPK. In summary, this is the first report demonstrating that AZD1208 inhibits growth of liposarcoma cells and that this activity is mediated through Pim-3 kinase, STAT-3, mTOR, S6 and AMPK expression and phosphorylation pathways.
机译:PIM激酶的过度表达在许多血液学和固体癌症中具有致癌/促生物作用。 AZD1208是一种泛PIM激酶抑制剂,具有抗癌和抗脂肪作用。在这里,我们研究了AZD1208对93T449细胞生长的影响,分化的人脂质瘤细胞系。在20 mu m,AZD1208是细胞毒性(细胞抑制的),但不凋亡,降低细胞存活,没有DNA碎片,胱天冬酶活化或亚G1相中增加的细胞;已知的凋亡参数。值得注意的是,AZD1208在93T449细胞中降低了信号传感器和转录-3(STAT-3)的活化剂的磷酸化。 AG490的Stat-3抑制作用,JAK2 / Stat-3抑制剂类似地降低细胞存活率。 AZD1208哺乳动物乳蛋白(mTOR)和核糖体S6的哺乳动物靶标的下调磷酸化,同时上调真核引发因子-2(EIF-2)。此外,AZD1208诱导了LKB-1-1-1-1-无关的AMPK活化,这对于其细胞抑制效应至关重要,因为AMPK的倒闭极大地阻止了降低细胞存活的能力。 AZD1208对PIM激酶家族(PIM-1和PIM-3)的两种成员的表达无效,但抑制了4EBP-1的磷酸化,PIM激酶的下游效应。重要的是,在AZD1208的动作中对PIM-3的核心作用被淘汰证实,这不仅降低了93T449细胞存活率,而且还导致了4EBP-1,MTOR,EIF-2和Stat-3的抑制作用随着AMPK的激活。总之,这是第一个报告证明AZD1208抑制脂肪糖瘤细胞的生长,并且该活性通过PIM-3激酶,STAT-3,MTOR,S6和AMPK表达和磷酸化途径介导。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号